News about "AstraZeneca"

AstraZeneca Rolls Out Anti-Complement Therapy for aHUS and PNH

AstraZeneca India launches Eculizumab (300 mg, 10 mg/ml), the first approved anti-complement therapy in India for the treatment of atypical Haemolytic Uremic Syndrome (aHUS) and Paroxysmal Nocturnal Hemoglobinuria (PNH), following CDSCO approval in January 2025 for import, sale and distribution.

AstraZeneca | 09/09/2025 | By Dineshwori

AstraZeneca's Baxdrostat Achieves Significant Blood Pressure Reduction in Phase-III Study

The BaxHTN phase-III trial showed Baxdrostat, an investigational drug developed by AstraZeneca, significantly lowered systolic blood pressure in patients with hard-to-control hypertension, achieving both statistical and clinical relevance.

AstraZeneca | 01/09/2025 | By Dineshwori

US Tariffs on EU Pharma Imports Threaten Drug Access and Innovation, GlobalData Warns

The US-EU trade deal has placed the pharmaceutical industry under significant fiscal strain, with consequences that extend beyond short-term financials, according to GlobalData, a leading data and analytics company.

AstraZeneca | 05/08/2025 | By Dineshwori |  133

AstraZeneca Reports 11 Percent Revenue Growth, Commits to USD 50 Bn US Expansion

For H1 2025, AstraZeneca’s total revenue rose 11 percent at constant exchange rates (CER) to USD 28.0 billion, driven by double-digit growth in both its oncology and biopharmaceuticals divisions.

AstraZeneca | 29/07/2025 | By Dineshwori |  112

AstraZeneca's Imfinzi Granted Priority Review by FDA for Early-Stage Gastric and GEJ Cancers

The US Food and Drug Administration (FDA) has accepted AstraZeneca’s supplemental Biologics License Application (sBLA) for Imfinzi (durvalumab) and granted Priority Review for the treatment of patients with resectable, early-stage and locally advanced (Stages II, III, IVA) gastric and gastroesophageal junction (GEJ) cancers.

AstraZeneca | 28/07/2025 | By Dineshwori

Syneron Bio Signs Strategic Partnership with AstraZeneca

Under this collaboration, AstraZeneca will gain access to Syneron Bio's innovative Synova™ platform, an intelligent and high-throughput macrocyclic peptide drug research and development platform, designed to support the advancements of research programmes exploring possible future treatments of chronic diseases.

AstraZeneca | 24/03/2025 | By Aishwarya |  721

AstraZeneca Signs License Deal with Alteogen for ALT-B4

Under the terms of the agreement, AstraZeneca will acquire worldwide rights to use ALT-B4 to develop and commercialise subcutaneous formulations of several oncology assets.

AstraZeneca | 18/03/2025 | By Aishwarya |  209

CHMP Recommends T-DXd EU Approval in HER2-Low/Ultralow Breast Cancer

ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca.

AstraZeneca | 04/03/2025 | By Aishwarya |  152

AstraZeneca To Invest CAD 820 Mn in Canada to Boost Clinical Delivery Sector

New investment in Canada will contribute to AstraZeneca’s global ambition to achieve USD80 billion in Total Revenue and to bring 20 new medicines to patients around the world by 2030 of which eight new medicines have been delivered to date.

AstraZeneca | 27/01/2025 | By Aishwarya |  207

AstraZeneca Gains CDSCO Nod for Import of Eculizumab in India

Eculizumab is a monoclonal antibody used to treat Paroxysmal Nocturnal Hemoglobinuria (PNH) and Atypical Hemolytic Uremic Syndrome (aHUS) by inhibiting complement-mediated thrombotic microangiopathy.

AstraZeneca | 18/01/2025 | By Aishwarya |  202